OverviewSuggest Edit

Zosano Pharma is a private pharmaceutical company focused on creating better products with their innovative drug delivery technology. Their lead program, parathyroid hormone (PTH) transdermal micro projection delivery system has finalized a Phase 2 clinical trial for treating severe osteoporosis. Zosano's objective is to discover and develop therapeutic drug candidates which address large unmet medical needs or have a significant potential for commercialization.
TypePublic
Founded2006
HQFremont, CA, US
Websitezosanopharma.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2018)53(+4%)
Job Openings10
Share Price (Jun 2021)$0.9
Cybersecurity ratingAMore

Key People/Management at Zosano Pharma

Steven A. Elms

Steven A. Elms

Director
Steven Lo

Steven Lo

President and Chief Executive Officer
Linda Grais

Linda Grais

Director
Christine Matthews

Christine Matthews

Chief Financial Officer
Kenneth R. Greathouse

Kenneth R. Greathouse

Director
Hayley Lewis

Hayley Lewis

Senior Vice President, Operations
Show more

Zosano Pharma Office Locations

Zosano Pharma has an office in Fremont
Fremont, CA, US (HQ)
34790 Ardentech Ct
Show all (1)

Zosano Pharma Financials and Metrics

Zosano Pharma Revenue

USD

Net income (Q1, 2020)

(18.9k)

EBIT (Q1, 2020)

(18.9k)

Market capitalization (11-Jun-2021)

100.4m

Closing stock price (11-Jun-2021)

0.9
Zosano Pharma's current market capitalization is $100.4 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

47.4k15.3k33.3k32.6k35.5k160.4k87.4k34.3k

Operating expense total

47.4k15.3k33.3k32.6k35.5k160.4k87.4k34.3k

EBIT

(47.4k)(15.3k)(33.3k)(32.6k)(35.5k)(160.4k)(87.4k)(34.3k)

Pre tax profit

87.4k34.3k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

General and administrative expense

5.8k15.6k21.1k3.1k4.5k5.7k22.1k3.6k4.6k10.9k9.6k3.4k7.4k11.5k6.5k77.0k50.3k21.2k19.9k24.0k21.2k4.8k4.4k10.4k18.9k

Operating expense total

5.8k15.6k21.1k3.1k4.5k5.7k22.1k3.6k4.6k10.9k9.6k3.4k7.4k11.5k6.5k77.0k50.3k21.2k19.9k24.0k21.2k4.8k4.4k10.4k18.9k

EBIT

(5.8k)(15.6k)(21.1k)(3.1k)(4.5k)(5.7k)(22.1k)(3.6k)(4.6k)(10.9k)(9.6k)(3.4k)(7.4k)(11.5k)(6.5k)(77.0k)(50.3k)(21.2k)(19.9k)(24.0k)(21.2k)(4.8k)(4.3k)(10.3k)(18.9k)
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.4k166.0164.0

Prepaid Expenses

12.0k

Current Assets

15.4k716.0164.012.0k

PP&E

996.0496.0
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

14.3k38.8k15.4k15.3k8.7k4.7k2.2k424.0106.01.4k384.0451.0

Prepaid Expenses

24.0k18.0k6.0k

Current Assets

23.8k38.8k15.4k15.3k8.7k4.7k2.7k974.0656.01.4k384.0451.024.0k18.0k6.0k

Total Assets

23.8k38.8k15.4k15.3k8.7k4.7k7.1k4.9k1.8k2.3k1.1k1.1k24.0k18.0k6.0k
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(47.4k)(15.3k)(33.3k)(32.6k)(35.5k)(160.4k)(87.4k)(34.3k)

Depreciation and Amortization

1.1k500.0125.0

Accounts Payable

2.1k(4.8k)(2.0k)4.0k5.6k(3.8k)

Cash From Operating Activities

(40.8k)(18.1k)(37.2k)(28.7k)(29.9k)(149.2k)(47.9k)(25.6k)
USDQ1, 2012

Financial Leverage

1.7 x
Show all financial metrics

Zosano Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Zosano Pharma Online and Social Media Presence

Embed Graph

Zosano Pharma News and Updates

Thinking about buying stock in Zosano Pharma, Lizhi, Nokia, Cleveland-Cliffs, or Jaguar Health?

NEW YORK, May 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, LIZI, NOK, CLF, and JAGX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain

FREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was…

Thinking about buying stock in AMC Entertainment, 22nd Century Group, Zosano Pharma, Pieris Pharmaceuticals, or 9 Meters Biopharma?

NEW YORK, April 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, XXII, ZSAN, PIRS, and NMTR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study –

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zillow Group and Zosano Pharma and Encourages Investors to Contact the Firm

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Zillow Group, Inc. (NASDAQ: Z) and Zosano Pharma Corporation (NASDAQ: ZSAN) on behalf of long-term stockholders. Mor…

Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference

FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference…
Show more

Zosano Pharma Blogs

Zosano Pharma Reports First Quarter 2021 Financial Results

FREMONT, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 , as well as business highlights. “We have gained clarity from the FDA on the

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results

FREMONT, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020 , as well as business highlights.

Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA Content Import Mon, 02/01/2021 - 08:02 Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA Feb 01, 2021 This release is a backfill from a News Wire …

Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA

FREMONT, Calif. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™

Zosano Pharma to Present at the Cantor Virtual Global Healthcare Conference

FREMONT, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the Cantor Virtual Global Healthcare Conference on

Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

FREMONT, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
Show more

Zosano Pharma Frequently Asked Questions

  • When was Zosano Pharma founded?

    Zosano Pharma was founded in 2006.

  • Who are Zosano Pharma key executives?

    Zosano Pharma's key executives are Steven A. Elms, Steven Lo and Linda Grais.

  • How many employees does Zosano Pharma have?

    Zosano Pharma has 53 employees.

  • Who are Zosano Pharma competitors?

    Competitors of Zosano Pharma include EMS Pharma, Biocon and Livzon Pharmaceutical Group.

  • Where is Zosano Pharma headquarters?

    Zosano Pharma headquarters is located at 34790 Ardentech Ct, Fremont.

  • Where are Zosano Pharma offices?

    Zosano Pharma has an office in Fremont.

  • How many offices does Zosano Pharma have?

    Zosano Pharma has 1 office.